Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.61 |
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.55 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12777781 | 0.87 | EGLN1 (0.67) | EGLN1EGLN3EGLN2 | |
| SCHEMBL2086426 | 0.82 | KDM4E (0.51) | KDM4E | |
| SCHEMBL8247279 | 0.79 | EGLN1 (0.72) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL5307125 | 0.78 | EGLN1 (0.61) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL8238459 | 0.78 | EGLN1 (0.67) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL8250095 | 0.78 | EGLN1 (0.70) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL8238446 | 0.77 | EGLN1 (0.72) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL1960754 | 0.77 | EGLN1 (0.71) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL8244419 | 0.77 | EGLN1 (1.00) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL8247257 | 0.76 | EGLN1 (0.60) | EGLN1EGLN3EGLN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | claimed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | claimed |
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| WO-2007103905-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN3 3/4885EGLN2 2/4885 |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN3 3/4885EGLN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.